118
Participants
Start Date
June 30, 2010
Primary Completion Date
June 30, 2014
Study Completion Date
September 30, 2014
MM-121
MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
Placebo
Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
Exemestane
Exemestane (25 mg) administered orally once per day
Vall d'Hebrón University Hospital, Barcelona
Hospital Clinic (Barcelona), Barcelona
Hospital Parc Tauli - Barcelona, Barcelona
Servicio de Oncología Médica / Hospital Universitario Gregorio Marañón, Madrid
Puerta de Hierro, Madrid
Pasco-Pinellas Oncology, New Port Richey
Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie
Achieve Clinical Research, Birmingham
Achieve Clinical Research, Birmingham
Tennessee Cancer Specialists Oncology Clinical Trials Center for Biomedical Research, Knoxville
Tennessee Cancer Specialists, Oncology Clincial Trials Center for Biomedical Research, Knoxville
Indiana University Simon Cancer Center, Indianapolis
Horizon Oncology Center, Lafayette
Rush University Medical Center, Chicago
Brustzentrum HS Kliniken Wiesbaden, Wiesbaden
Onkogologisches zentrum Munich, Munich
Arizona Center for Cancer Care, Glendale
Beverly Hills Cancer Center, Beverly Hills
Southwest Cancer Center, Escondido
Pacific Cancer Medical Center, Anaheim
Wilshire Oncology Medical Group, Inc., Corona
Central Coast Medical Oncology Corporation, Santa Maria
Hematology Oncology Associates, INC., Oakland
San Jose Medical Center, San Jose
Railway Clinical Hospital, Saint Petersburg
Leningrad Regional Oncology Center, Saint Petersburg
City Clinical Oncology Center, Saint Petersburg
Massachusetts General Hospital, Boston
Hopital Maissoneuve-Rosemont, Montreal
McGill University Jewish General Hospital, Montreal
Hopital du Sacre-Coeur de Montreal, Montreal
CHA St. Sacrement, Québec
Medico-Diagnostically Center of International Institution of biological systems n.a.S.M., Berezina
Lead Sponsor
Merrimack Pharmaceuticals
INDUSTRY